Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy
Abstract Immunotherapy has revolutionized cancer treatment; however, only 10–30% of patients experience durable survival benefits, while most malignancies remain resistant. In melanoma, vitiligo‐like depigmentation is a frequent and generally mild immune‐related adverse event, whose presence correla...
Salvato in:
| Autori principali: | , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wiley
2025-11-01
|
| Serie: | Advanced Science |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1002/advs.202503979 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|